Author: admin

  • Luis Suarez ban for spitting extended to 9 matches by MLS – Tribuna.com

    1. Luis Suarez ban for spitting extended to 9 matches by MLS  Tribuna.com
    2. Major League Soccer Announces Disciplinary Action Following Leagues Cup Final  MLSsoccer.com
    3. Suarez gets three-match MLS ban for Leagues Cup spitting  The Express Tribune
    4. Luis Suarez’s punishment increases: MLS reveals additional sanctions to the Leagues Cup  MARCA
    5. Is ‘spitting’ a new norm in sports for venting out anger? NFL must learn from MLS after Luiz Suarez handed  The Economic Times

    Continue Reading

  • Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

    Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

    In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus pembrolizumab—was associated with a median progression-free survival that compared favorably with historical controls, based on data presented during the 2025 ASCO Annual Meeting.1 The prospective clinical trial also appeared to result in less upfront exposure to platinum doublet chemotherapy than would be expected with assessment of the PD-L1 tumor proportion score.

    “There is clinical uncertainty as to which patients require first-line treatment with chemoimmunotherapy vs immune checkpoint inhibitor monotherapy,” according to Julia K. Rotow, MD, Clinical Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and Assistant Professor of Medicine, Harvard Medical School, Boston, and colleagues. “Although PD-L1 expression can predict for immune checkpoint inhibitor response, it is an imperfect biomarker. Early circulating tumor DNA [ctDNA] kinetics may offer an individualized assessment of treatment response, allowing us to optimize clinical decision-making.”

    Study Design

    A total of 40 patients received first-line treatment with pembrolizumab. On the first day of the second cycle, 36 completed plasma response assessment. Plasma response was defined as a reduction of at least 50% in the maximum variant allele fraction and/or persistent low-shedding status. Radiographic response was assessed at the third cycle.

    Patients who showed a radiographic response or had radiographic stable disease along with a plasma response continued pembrolizumab monotherapy. Those with stable disease or asymptomatic disease progression but without a plasma response were escalated to a combination of carboplatin-based doublet chemotherapy (paclitaxel for squamous histology or pemetrexed for nonsquamous) plus pembrolizumab. Patients who experienced symptomatic radiographic disease progression discontinued treatment.

    “Early circulating tumor DNA kinetics may offer an individualized assessment of treatment response, allowing us to optimize clinical decision-making.”

    — JULIA K. ROTOW, MD

    Tweet this quote

    According to the investigators, based on the integrated plasma and radiographic response assessment, 21 patients were assigned to continue with pembrolizumab monotherapy, and 19 patients received this treatment (7 with radiographic partial response at cycle 3 and 12 with radiographic stable disease with plasma response). And nine plasma nonresponders with radiographic stable disease were assigned to escalate to pembrolizumab plus platinum doublet therapy, and seven patients received this therapy. Reasons for treatment discontinuation prior to cycle 3 treatment allocation included disease progression (n = 3), adverse events (n = 2), or death (n = 1). Age, gender, performance status, histology, and PD-L1 tumor proportion score were found to be similar across the treatment arms.

    The primary endpoint was the 6-month progression-free survival rate with the platinum doublet therapy. Safety, feasibility, and survival outcomes were evaluated as secondary endpoints, according to Dr. Rotow.

    Key Results

    The overall response rate with this adaptive treatment strategy was 50%; stable disease was reported in 22.5% of patients. Those with vs without plasma response experienced a higher radiographic response rate (81% vs 21%). The median durations of progression-free and overall survival were 11.0 and 14.9 months, respectively.

    Toxicities were found to be consistent with the known adverse event profiles of platinum doublet chemotherapy and pembrolizumab, according to Dr. Rotow. “The rates of grade 3 or higher adverse events were very low,” she noted. Three patients with high PD-L1 tumor proportion scores and a history of tobacco use died during their first two cycles of pembrolizumab monotherapy; two died of disease progression, and one died of a treatment-unrelated adverse event.

    “[Based on subgroup analyses], both progression-free and overall survival were similar among PD-L1–high and PD-L1–low subsets,” Dr. Rotow commented. “However, plasma response predicted strongly for improved [outcomes].” The median progression-free survival was 16.4 months in patients with a plasma response and 4.8 months in those without (hazard ratio [HR] = 0.34); the median overall survival was 34.3 and 8.6 months, respectively (HR = 0.15).

    On study, a total of 16% of PD-L1–high patients ultimately received chemoimmunotherapy instead of standard immunotherapy alone; most with PD-L1–low disease (80%) received immunotherapy rather than standard chemoimmunotherapy. “Fewer patients were treated with platinum doublet chemotherapy than would have been predicted by PD-L1 status alone (17.5% vs 37.5%),” noted Dr. Rotow and colleagues. Overall, 50% of patients received platinum doublet therapy either on study or as their next line of treatment, and 68.8% remained free of disease progression on a platinum doublet at 6 months.

    Dr. Rotow concluded: “Plasma-guided intensification from immunotherapy monotherapy to platinum doublet [plus] pembrolizumab is feasible in metastatic NSCLC, resulting in a median progression-free survival of 11.0 months, with fewer exposed to platinum doublet chemotherapy than might have been predicted by standard clinical biomarkers. ctDNA predicted strongly for both progression-free survival and overall survival in this patient population, and ctDNA kinetics is an important emerging tool to guide clinical decision-making in upfront therapy in NSCLC, though further validation within a randomized study is needed to clarify the implications for clinical practice.”

    DISCLOSURE: Dr. Rotow has received honoraria from AstraZeneca, Daiichi Sankyo, and Pfizer; has served as a consultant or advisor to AbbVie, Amgen, AstraZeneca, BioAtla, BMS, Boehringer Ingelheim, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Jazz Pharmaceuticals, Johnson & Johnson/Janssen, Merus, Nuvation Bio, Pfizer, Sanofi/Regeneron, Summit Therapeutics, and Takeda; has received research funding from AbbVie, Altor BioScience, AstraZeneca, BioAtla, Black Diamond Therapeutics, Blueprint Medicines, Daiichi Sankyo, DualityBio, Enliven Therapeutics, EpimAb, ImmunityBio, Loxo, ORIC Pharmaceuticals, RedCloud Biotech, Regeneron, Summit Therapeutics, and Synthekine; and has received reimbursement for travel, accommodations, or expenses from AstraZeneca, Black Diamond Therapeutics, BMS, Johnson & Johnson/Janssen, and Merus. For full disclosures of the other study authors, visit coi.asco.org.

    REFERENCE

    1. Rotow JK, Heavey G, Nishino M, et al: Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer. 2025 ASCO Annual Meeting. Abstract 8515. Presented June 2, 2025.

    Continue Reading

  • Apple Event live updates 2025: Last minute leaks on iPhone 17, AirPods 3, Apple Watch Series 11, more

    Apple Event live updates 2025: Last minute leaks on iPhone 17, AirPods 3, Apple Watch Series 11, more

    By Kerry Wan, Managing Editor / Sept. 6 at 3:27 p.m. ET

    An ultra-thin and light iPhone would be refreshing to see from Apple, as its current four-iPhone lineup has remained in place since the iPhone 12 series in 2020. 

    The iPhone 17 Air will reportedly feature a large display size, a titanium frame, and a revamped camera bar with only a single sensor.

    Also: If these iPhone 17 Air rumors are real, my old phone is about to be retired

    Apple is also expected to replace the iPhone 17 Plus with the iPhone 17 Air, as consumers have shown the least interest in the former model. This potentially positions the Air model as both the best big iPhone that doesn’t cost as much as the Pro Max and the most portable for those who want that.

    Zoom out a bit, and you might even be looking at the beginnings of what an iPhone Fold experience could be like in a year or two.


    Continue Reading

  • Derek Kolstad Turning ‘Normal’ Guys Bob Odenkirk & Keanu Reeves into action heroes

    Derek Kolstad Turning ‘Normal’ Guys Bob Odenkirk & Keanu Reeves into action heroes

    EXCLUSIVE: After creating the John Wick and Nobody action franchises, screenwriter Derek Kolstad is at it again. Premiering last night in the Midnight Madness section at TIFF as an acquisition title – I’ll eat my hat if it doesn’t get a distribution deal as Kolstad already ponders a sequel – comes Normal. The star is Nobody protagonist and Better Call Saul star Bob Odenkirk, this time as a temp sheriff in a Fargo-like snowy town that turns out to be where the Yakuza keeps its stash of ill-gotten cash and gold. The Ben Wheatley-directed tongue in cheek actioner also stars Henry Winkler and Lena Headey, and a lot of shit gets blown up. I’m not sure the real Odenkirk could beat me up, but he’s once again ideal as the reluctant action hero ruining the white snowy streets with splashes of red. Kolstad here reveals the care and feeding that goes into creating these unlikely action hero franchises, starting with John Wick, who carries the name of his grandfather.

    DEADLINE: You’ve done things different in creating two action franchises and you’re at TIFF with what might be the third. Start with your decision to kill John Wick’s puppy in the first film. I remember watching I Am Legend with my kids, and how upset they got when Will Smith’s dog got killed. I reminded them that every human being on earth also bought the farm, but they were unmoved. You made it even worse by killing a puppy given him by his dead wife. Explain.  

    KOLSTAD: The dog? It’s funny because when I was a kid, the movie that really screwed me up was Old Yeller. Disney put out those white-bordered VHS tapes and it’s a really sweet movie until Old Yeller gets put down. And then of course reading Where the Red Fern Grows in fifth grade in school. I beat everyone to the end and just sat there crying. There was something special about that ultimate innocence of a puppy. I spent so much time on the world building of John Wick and what’s taking place in the background, and the texture. I thought that I knew I was doing something a little bit off kilter. My wife Sonia is the first line of defense, she reads the first draft of everything. I hear her in the other room, hitting page 11, 12, or whatever it was, and she just started going, Nope! Nope! I got the script back with a big X. It’s the one thing we disagreed on and it turned out the way it did. But also even you look at Nobody, you could say it was all about a kitty cat bracelet, but it’s not. It’s like you could say it’s about a puppy, but it’s not. But then again, sometimes the puppy and the bracelet, it becomes the straw that breaks the camel’s back.

    DEADLINE: So now you’ve evoked the image of a camel with a broken back. Were you pressured to change the dead puppy?  

    KOLSTAD: The first cut of the movie, certain powerful people with notes come back and say, first thing we got to do is get rid of the dog. And you’re just like, wait, wait, wait, wait. To their credit, man, since day one, Chad [Stahelski] and Dave [Leitch] fought for that because they understood it. Keanu Reeves fought for it, he understood it, but ultimately it was a flash of negativity in the pan, and once they decided to go with it, everyone was behind it.

    I think it helped because this is the way I put it. I have 8-year-old twins. They’re too young to see the movie. And about a year ago, I showed them one of the trailers, the general audience one, which is already too violent for them. ‘Did they kill the dog, daddy?’ I said, yes. And then, ‘well, what is he doing about it?’ And I said, ‘killing them all.’ And the response, in a very small voice was, ‘good.’ From the lips of a child.

    DEADLINE: John Wick was the name of your grandfather. How many hundreds of people did your grandfather kill?

    KOLSTAD: He’s nothing like that character. In fact, he never saw the movies. The last R-rated movie he ever saw, he took my grandma to see The Piano in the early nineties and was just like, yeah, I’m done with R-rated movies. There’s a lot of nudity there. I argued, there’s no nudity in John Wick. And he’s like, nah. But he was always so happy because I’d wanted to be a screenwriter since the age of eight or nine, I loved books, loved movies and was like, I’ll be that guy. And so for this to actually work out, man, we had a special connection there.

    DEADLINE: When I watched Normal, I felt like I did with John Wick an Nobody. I am not a violent person, but I could watch it on a loop. I’ve talked about this with Chad, that I cannot even describe why I feel that way. It’s almost meditative, despite the carnage and body counts. Why are your creations so damn watchable?

    KOLSTAD: It’s funny because half of the answer is there’s a catharsis at play, right? I would also argue that in talking with Bob and talking to Keanu and a lot of the other guys I’ve been working with, they recognize that a good fight sequence is a dance number.

    You look at these two guys and these two franchises, and they already come in with a great deal of goodwill. They’re good people, both in the public eye and on set. John Wick is not an anti-hero, he’s a hero in who he was and who he is and who’s going to be. I think part of the reason is you sit down, you relax, and you enjoy. They’re not too long, they’re not too short. They feel the right amount of length, and you’re just like, that made me feel good. It’s one of the reasons I go back and I watch Long Kiss Goodnight or Die Hard or Hunt for Red October or Predator over the years. I love Cabin in the Woods. We all have our 20 movies that when we travel and turn on the TV and there’s that one movie on at two in the morning, you’re like, well, shit, I have to watch the rest of it. That’s kind the goal for me.

    DEADLINE: I’ve got my go-to films, and always had that relationship with the Equalizer trilogy and with the movie Payback, the one that Mel Gibson was in. All he wanted was the $70,000 he’d been screwed out of?

    KOLSTAD: Dude, my favorite line in both that and Point Blank, I think they had the same line. It was, I’ll pay you the $79,000 or whatever the number, and Mel goes, I don’t want your money. I want my money. And he realized, oh, this guy’s kind of insane. And it’s just a joy.

    DEADLINE: What were your touchstones in creating John Wick, Nobody and Normal?  

    KOLSTAD: I’m a big fan of Spencer Tracy, and so I went into this idea for Normal because I love Bad Day at Black Rock. I wrote out this treatment when I couldn’t sleep one night and Mark Provissiero, Bob’s manager and the producer on this, he had asked me what I was working on. I pitched him this thing and he’s like, that sounds awesome. Then we both got super busy and finally Bob calls me and said, what’s this thing you mentioned? I pitched him and got, that sounds awesome. It was just lightning in a bottle because the way I work with Bob is, I bring in my love of genre and he brings in his love of comedy and character. I build out the story, the world, build the action, I populate it. But he comes in and he spends just as much time with everybody else in the script. We have a shorthand. But mainly it’s a love letter to the stuff I loved as a kid.

    DEADLINE: You killed something else lovable, not as bad as the puppy, but…

    KOLSTAD: And every time I see that scene, it kills me because it is so funny.

    DEADLINE: We’d seen Keanu in action films, but Odenkirk is an unlikely action hero. Then again, Liam Neeson was this serious actor known for Schindler’s List and Jason Statham was this fast talking funny guy in Guy Ritchie movies and they’ve made careers in action.  How did you know Bob would be good at this?

    KOLSTAD: Bob says it best, and it’s that he came for the world of sketch comedy where the sketches are between two and a half to six minutes. And he said that’s what a fight is. And he’s right. A good fight scene is around that time and he’s like, it begins this dance. Both he and Keanu especially, they loved to say…pain is the wrong word, but they both put their bodies through the ringer. They’ll both be the first to say, I can’t really fight, but I can film fight. And they just get excited about it. The stunt crews love Bob and Keanu. They work hard, they love the craft, and they become friends with the crew. And when the crew wants to switch something up or Bob’s got an idea to make the scene a little funnier, or Keanu’s got an idea that is more of a character moment, it just becomes this perfectly oiled machine. But I also remember seeing Geena Davis in Long Kiss Goodnight and going, holy shit. And I think again, we said the same thing about comedians who go and do dramatic parts. They just see a new challenge that they haven’t done and they just embrace it.

    DEADLINE: If Normal gets a Toronto deal and becomes a hit, do you want to do more as happened with John Wick and Normal?

    KOLSTAD: That’s the hope in everything I do. I think back to Star Wars when I was a little kid, you hear the name Jabba the Hut and you’re like, what? And you expect to see him in Empire Strike back, and you don’t, but there he is in the third film. You plant these seeds and hope for a creative harvest. The weight you put on yourself is to make sure that the first one works. Then, if there’s only one, you’re happy, and if the studio or the investors come back and say, let’s do another, you have to make sure it’s about we got to make sure that it’s the character’s evolution. You can trust me with the action and the world building and cool bad guys and all that kind of stuff. But if your character doesn’t change, it’s the end of the franchise, right?

    Continue Reading

  • Sombr Makes His Entrance | Vogue

    Sombr Makes His Entrance | Vogue

    A few days before Shane Michael Boose—the 20-year-old musician known as Sombr—stole the show at Sunday’s MTV Video Music Awards, performing his hits “Back to Friends” and “12 to 12” for his biggest—and most staggeringly starry—audience yet, he found himself in a stately room on the second floor of New York’s Nine Orchard hotel.

    Enjoying some rare downtime between rehearsals, he was dressed in a navy blazer, a black T-shirt, and ripped jeans. Despite his high-pressure weekend, he’s in a cheery mood. “You’re getting happy Sombr today,” he tells me, pleasantly.

    And why might that be? For one thing, he’s just met one of his rock idols at the hotel, which sits just around the corner from where Boose grew up, on New York’s Lower East Side. “It’s someone I get compared to a lot, and he said my name first,” Boose says, mimicking an English accent. “That’s one hint, but that’s all you get. I called my sister and she was like, ‘What?!’ And now I’m going to be happy all day.”

    Such surreal moments have seemed to come one right after the other. Not so long ago, Boose was a LaGuardia dropout with a dream; now, in an era where guitar-driven acts are a dime a dozen, he’s managed to lodge three songs from I Barely Know Her, his recently released debut album, in the Hot 100. To celebrate the launch, he shut down the corner of Canal Street and Orchard for a free surprise show.

    So, what’s it like when you suddenly get everything you want? Before Boose went back on the road for his Late Nights & Young Romance Tour, Vogue sat down with him to find out.

    Vogue: You’ve had an incredible year so far. How have you been navigating it all?

    Sombr: I remember a year and a half ago, I was feeling really low about the point I was at in my career. And even then, I was still so privileged—just being able to do it full-time and play shows. But at the time I made a video where I was just talking to myself and manifesting where I wanted to go. And watching that video back now, it’s so crazy, because the version of me in that video, if he found out I was anywhere near where I am today, he would fucking lose his mind. One thing I don’t understand is that artists will get to a certain point and all they’ll do is complain about how hard it is to be famous. It’s like, you are so privileged. Fucking be grateful. Obviously, every job has its hardships. Oh my God, someone recognizes you on the street—how brutal! So I try to remain super grateful, you know?

    Continue Reading

  • Scott Dixon Already Fired Up for 2026 after Consistent Season

    Scott Dixon Already Fired Up for 2026 after Consistent Season

    Scott Dixon continued his hallmark consistency in the NTT INDYCAR SERIES by securing third place in the 2025 championship standings.

    Driving the No. 9 PNC Bank Chip Ganassi Racing Honda in 2025, the six-time series champion added yet another impressive chapter to his legendary career.

    Dixon captured victory at the Honda Indy 200 at Mid-Ohio presented by the All-New 2026 Passport on July 6, extending his record streak to 21 consecutive seasons with at least one victory. Next best is Will Power, who had 16 straight seasons with a win between 2007-2022, followed by 11 years in a row from Bobby Unser (1966-76).

    Dixon has won at least one race in 23 of his 25 seasons.

    Dixon this season also passed Mario Andretti (407 starts) for the most career starts in INDYCAR history, doing so in the 109th Running of the Indianapolis 500 presented by Gainbridge. He reached start No. 419 at Nashville Superspeedway, the season finale.

    But despite what looks like another strong season on paper, being tied with Christian Lundgaard and Power for third-most top-five finishes this season (six), having the second-most top-10 finishes (12) and securing his 19th top-four points finish in the last 23 seasons, Dixon offered a more measured assessment.

    “I think for where we are in the championship, mind-boggling,” Dixon said. “But I think it also shows just, you know, a lot of people have had pretty horrible years, with the exception of Alex (Palou). So, it’s been an interesting year, and I’m looking forward to moving on to next year.”

    Dixon (photo, above) has enjoyed the best vantage point to witness Palou’s dominance. Since joining Chip Ganassi Racing in 2021, Palou has claimed four of the last five championships, including three straight. Dixon last won the title in 2020 and has only finished ahead of Palou once – in 2022 — when he placed third and Palou was fifth.

    This season, Palou collected eight wins, including a victory in the 109th Running of the Indianapolis 500 presented by Gainbridge, and clinched the title with two races remaining. His dominance cast a long shadow over the rest of the field and emphasized how uneven many of the typical competitors for the championship performed.

    Josef Newgarden, who had earned multiple victories in each of his first eight seasons with Team Penske, only won the season finale at Nashville Superspeedway and ended the year 12th in the standings. Will Power was Penske’s highest finisher in ninth, while Scott McLaughlin went winless and finished 12th in points. Colton Herta, the 2024 championship runner-up, also failed to reach victory lane.

    “I just feel like the usual suspects or people that have been fighting for a championship really didn’t have it this year,” Dixon said.

    Still, Dixon remains optimistic. He and his Chip Ganassi Racing team plan to make targeted improvements during the offseason as he chases a record-tying seventh championship, which would place him alongside A.J. Foyt.

    “We’ll do our deep dives this offseason,” Dixon said. “There are a couple key things we can change that would definitely make life easier. We’ve had speed; we just didn’t always have it when we needed it.”

    Dixon knows what it takes to execute on race weekends. He holds a series-record 145 podiums. His 53 career second-place finishes are just three shy of Andretti’s record, and his legacy remains very much active.

    Dixon, 45, isn’t eyeing the exit just yet and expects to add to those exemplary accomplishments in the years to come.

    “If it doesn’t feel natural anymore, that’s when you know,” he said. “But I still feel like I’ve got a couple good years in me. The fire’s still there.”


    Continue Reading

  • NDMA predicts moderate to heavy rainfall in various areas – RADIO PAKISTAN

    1. NDMA predicts moderate to heavy rainfall in various areas  RADIO PAKISTAN
    2. Karachi sees light rain amid forecast for heavy showers  Dawn
    3. Heavy rainfall on the cards for Karachi  The Express Tribune
    4. Torrential rains likely to lash Karachi for next three days, cause urban flooding: PMD  Business Recorder
    5. Capital police issues rain safety advisory for citizens  The Nation (Pakistan )

    Continue Reading

  • Mental Health Disorders Associated With Shorter Life Expectancy in HIV Patients, Study Shows

    Mental Health Disorders Associated With Shorter Life Expectancy in HIV Patients, Study Shows

    People living with HIV and a comorbid mental health disorder have a higher rate of mortality than those without mental health disorders, according to recent research published in the Journal of the International AIDS Society. Loss of life years may be attributed to factors such as late ART initiation, lower engagement in care, increased risk of suicide and accidental deaths and higher incidences of physical illness.

    For this longitudinal cohort study, a team of researchers, including corresponding author Andreas D. Haas, from the University of Bern in Switzerland, used medical records and mortality data from clinical cohorts in South Africa and North America. Participants were followed between the years 2000 and 2021. Disorders such as depression, anxiety, psychotic disorders, and substance use disorders were identified using diagnostic codes. Life-years lost were calculated as the average difference in remaining life expectancy between patients with and without mental disorders, with a cutoff age of 85, due to average life expectancy in both regions.

    This study included more than a quarter of a million participants from South Africa and North America, specifically 119,785 participants from South Africa, 48% of whom had a mental health disorder, and 142,044 from North America, 66% of whom were diagnosed with a mental health disorder.

    For South African participants, the estimated life years lost were 3.42 years in males and 2.95 years in females.

    For North American participants, estimated life years lost were 4.16 in males and 4.64 years in females.

    Substance use disorder diagnoses were more prevalent in North America (37%) than in South Africa (1.5%). Depressive and anxiety disorders were the most prevalent disorders in both regions, accounting for approximately 45% of diagnoses in South Africa and 56% of diagnoses in North America.

    Mental health disorders such as depression and anxiety were associated with more natural deaths, such as old age. Natural death was calculated as a CD4 count below 200. In both regions, psychotic disorders and substance abuse disorders were associated with greater loss of life. Specifically, psychotic disorders were associated with a 7-to-9-year loss, and substance abuse was associated with a 4-to-10-year loss.

    Deaths associated with mental disorders in North America may be explained by higher rates of substance abuse compared with South Africa.

    “Among people living with HIV, the impact of mental health disorders on mortality is of particular concern because both HIV and mental illness can act as risk factors for physical comorbidities, such as diabetes or cardiovascular disease,” Haas and the team write in the study. “Improved management of HIV and physical comorbidities among PWH affected by mental health disorders may enhance their prognosis.”

    Disorders such as depression may also make it difficult for HIV patients to make it to their appointments or adhere to treatments, factors that are essential for long-term viral suppression and survival.

    Individuals with mental health disorders already have a lower life expectancy than the general population, with a reduced life expectancy ranging from 1 to 15 years less, according to the study. In addition, the prevalence of mental health disorders is also higher in people living with HIV compared to the general population.

    Continue Reading

  • Donnarumma features in Italy’s nine-goal thriller with Israel – Manchester City FC

    1. Donnarumma features in Italy’s nine-goal thriller with Israel  Manchester City FC
    2. Italy beat Israel in nine-goal qualifying thriller  BBC
    3. Gattuso praises Italy’s comeback against Israel but worried by fragility  Reuters
    4. Italy avoid disaster, Kosovo win in World Cup qualifying  Hindustan Times
    5. Israel vs. Italy: Official line-ups for 2026 World Cup qualifier  Football Italia

    Continue Reading

  • Dell CFO Yvonne McGill to leave, PC maker reaffirms forecasts

    Dell CFO Yvonne McGill to leave, PC maker reaffirms forecasts

    A Dell Technologies sign is seen in Round Rock, Texas, on June 2, 2023.

    Brandon Bell | Getty Images

    Dell Technologies said on Monday its Chief Financial Officer Yvonne McGill will resign effective Sept. 9 after roughly three decades with the company.

    David Kennedy, who has been with the PC maker for 27 years, will serve in the interim role. He is currently senior vice president of global business operations, finance.

    McGill will serve as an advisor through Oct. 31, the company said. Its shares were down 1.8% after the bell.

    “McGill’s decision to resign her position is not the result of any disagreements with the company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices,” Dell said.

    The company also reaffirmed its third-quarter and full-year forecasts issued last month.

    Continue Reading